FY2025 was more or less in line with our and CSS forecasts, demonstrating resilience amid global challenges and “setting up a foundation for future growth”. We maintain our prudence stance as -while FY2025 shows that Barco can return to sales and margin growth under difficult conditions- the year also exposed clear vulnerabilities—most notably in order intake, which fell 5% YoY (–2% at constant FX) and declined across several divisions and regions. The contraction in orders, combined with the st...
Adyen: Preview 2H25. Aperam: In-line 4Q25, upbeat medium-term outlook balances short-term consensus risk. Ayvens: Fast Car (UCS normalisation). Barco: 4Q25 preview, mixed performance. Lotus Bakeries: Another beat on every line. Orange Belgium: 2H25 EBITDAal beat on lower sales, much better 2026 guidance. Philips: CMD & 4Q25 preview, execution is key. RELX: FY25 preview. Universal Music Group: Peer Warner Music 4% revenue and 11% OIBDA beat
Yesterday evening an article was published in the local Antwerp newspaper GVA. It stated Flemish Minister of the Environment Jo Brouns (CD&V) has granted a permit for the Waterkracht project. As a result, all chemical companies in the Port of Antwerp will use purified wastewater to cool their production processes starting at the end of 2027. Earlier on the target was to start commercial operations early 2027 and this is still reflected in our earnings model. We will overhaul our model once it is...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the C...
Ekopak just announced a long term strategic partnership with an unnamed European infrastructure partner for the development of (large) WaaS projects. Many details are still unknown and management was not (yet) available for comments. The partnership introduces a minimum of €150m in off balance sheet funding over the next three years that will be deployed through dedicated asset companies financed with senior non recourse debt and majority equity from the infrastructure partner. As part of the pa...
Yesterday before US market opens, Autolus announced preliminary unaudited 4Q25 and FY25 net product sales of Aucatzyl (obe-cel, CD19 CAR-T), and provided a business update. $ 75m in FY25 Aucatzyl sales is in line with CSS ($ 75.9m) and ahead of our estimate of $ 72.5m. We believe this figure makes Aucatzyl's first year on the market a success, and we view FY26 guidance of $ 120-135m as within reach. Pipeline wise, we look forward to initial data from the phase 1 trial of Aucatzyl in the difficul...
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus anticipates full year 2026 AUCATZYL® net product revenue of $120 million to $135 millionIndependent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Focus for 2026 is: Driving AUCATZYL®...
We hosted our 29th ODDO BHF Forum in Lyon on 8 and 9 January 2026. In total, 220 companies presented over the two days. In the following note, we provide some initial feedback from the companies on Day 2, in addition to Day 1 feedback (Link to Day 1 feedback). Key positive companies were Corbion, DEME, Elia Group, Knorr Bremse, Sulzer, Séché Environnement, Fraport, Vallourec and TUI. More cautious companies were Arkema, Fastned, INWIT, Manitou, Roche Bobois, Téléperformance, and Colonial SFL. T...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.